Core Viewpoint - 旺山旺水-B (02630) experienced a significant drop of over 18% on its second day of trading after a previous surge of over 145%, with its current stock price still approximately double the IPO price of HKD 33.37 [1] Company Overview - 旺山旺水 was established in 2013 and is a biopharmaceutical company focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has developed a diversified pipeline of 9 innovative products, with 2 in commercialization, 4 in clinical stages, and 3 in preclinical stages [1] - In addition to its innovative drug pipeline, the company is also involved in the generic drug sector, with 3 products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1] Financial Performance - For the fiscal year 2023, the company recorded a revenue of RMB 200 million, with subsequent revenues of RMB 11.832 million, RMB 3.224 million, and RMB 12.958 million for the first four months of 2024 [1] - The company reported a net loss of RMB 218 million for 2024, compared to a net profit of RMB 6.427 million in 2023, with the fluctuation attributed to a decline in revenue [1]
港股异动 | 旺山旺水-B(02630)上市次日回吐逾18% 仍较招股价高约一倍